ArticleNeuropsychiatric disease and treatment2010
Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference.
Article in Neuropsychiatric disease and treatment, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Topiramate for the prophylaxis of episodic migraine in adults.The Cochrane database of systematic reviews · 2013Pooled it
- Geriatric Migraine, Geroscience, and Sustainable Development Goals: Bridging Clinical Complexity and Public Health Priorities.Journal of clinical medicine · 2026Review
- Phenotype-guided selection of venlafaxine and topiramate for vestibular migraine: a narrative review.Frontiers in neuroscience · 2026Review
- Current Trends in Management of Migraine: A Review of Current Practice and Recent Advances.CNS & neurological disorders drug targets · 2026Review
- Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs.Chemical reviews · 2025Review
- Enhancing Acute Migraine Treatment: Exploring Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for the Nose-to-Brain Route.Pharmaceutics · 2024Review
- PLGA Nanoparticles Based Mucoadhesive Nasal In Situ Gel for Enhanced Brain Delivery of Topiramate.AAPS PharmSciTech · 2024Article
- Migraine Pharmacological Treatment and Cognitive Impairment: Risks and Benefits.International journal of molecular sciences · 2022Review
- Rimegepant for the treatment of migraine.Health psychology research · 2022Article
- Eptinezumab-jjmr, a humanized monoclonal specific to Calcitonin Gene Related Peptide, for the preventive treatment of migraine in adults.Health psychology research · 2022Article
- Epilepsy and Migraine Shared Genetic and Molecular Mechanisms: Focus on Therapeutic Strategies.Molecular neurobiology · 2021Review
- Cannabis and Migraine: It's Complicated.Current pain and headache reports · 2021Review
- Lasmiditan for the Treatment of Migraines With or Without Aura in Adults.Psychopharmacology bulletin · 2020Review
- An Evidence-Based Review of Fremanezumab for the Treatment of Migraine.Pain and therapy · 2020Review
- Topiramate-Induced Acute Psychotic Symptoms: A Case Report.Clinical neuropsychiatry · 2020Article
- Contributions of Nociresponsive Area 3a to Normal and Abnormal Somatosensory Perception.The journal of pain · 2019Review
- Subcutaneous sumatriptan delivery devices: comparative ease of use and preference among migraineurs.Patient preference and adherence · 2017Article
- Topiramate-induced paresthesia is more frequently reported by migraine than epileptic patients.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2016Observational
- Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients.Medical devices (Auckland, N.Z.) · 2016Article
- Preventive agents for migraine: focus on the antiepileptic drugs.Journal of central nervous system disease · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is a very common disorder characterized by the combination of typical headache with associated autonomic symptoms and/or the presence of aura. Considerable advances have been made in recent years to understand the pathophysiology of migraine, which has led to improved treatment options for the acute migraine attack as well as migraine prophylaxis. Unfortunately, preventive treatment is often insufficient to decrease migraine frequency substantially or is not well tolerated. Topiramate is an antipileptic drug with a complex mode of action which has proven its efficacy and safety in the prophylactic treatment of episodic migraine in a number of randomized controlled clinical trials. Topiramate is also effective in treating patients with chronic migraine. It has little pharmacological interaction with other drugs and is generally well tolerated by patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.